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Abstract 
The ‘canonical’ proteasomal degradation signal is a substrate-anchored polyubiquitin chain. 
However, a handful of proteins were shown to be targeted following monoubiquitination. In this study, 
we established - in both human and yeast cells - a systematic approach for the identification of 
monoubiquitination-dependent proteasomal substrates. The cellular wild type polymerizable ubiquitin 
was replaced with ubiquitin that cannot form chains. Using proteomic analysis, we screened for 
substrates that are nevertheless degraded under these conditions compared to those that are stabilized, 
and therefore require polyubiquitination for their degradation. For randomly sampled representative 
substrates, we confirmed that their cellular stability is in agreement with our screening prediction. 
Importantly, the two groups display unique features: monoubiquitinated substrates are smaller than the 
polyubiquitinated ones, are enriched in specific pathways, and in humans, are structurally less 
disordered. We suggest that monoubiquitination-dependent degradation is more widespread than 
assumed previously, and plays key roles in various cellular processes. 
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Significance Statement 
Unlike the prevailing ‘canon’ that a polyubiquitin chain (with a minimal number of four 
moieties) serves as the most common proteasomal degradation signal, with only a few exceptional 
substrates targeted following monoubiquitination, we show here that this mode of proteasomal-
targeting modification is much more common. To demonstrate it, we designed a screen that employs a 
proteomic analysis to identify cellular proteins that are degraded in the exclusive presence of non-
polymerizable ubiquitin. The screen revealed numerous such substrates, suggesting that this mode of 
proteasomal recognition is more widespread than assumed previously. Importantly, the screen 
revealed also the proteins that require polyubiquitination for their degradation, as they are stabilized in 
the presence of the non-polymerizable ubiquitin. For randomly selected individual substrates, we 
confirmed that their mode of modification and subsequent degradation is in agreement with the 
predictions, corroborating the reliability of the screen. Notably, the two classes of proteins modified 
by the two different modes of ubiquitination display certain distinct important characteristics. 
Monoubiquitinated proteins appear to be of lower molecular mass, of lesser structural disorder, and 
can be assigned to defined cellular pathways/processes. Furthermore, some of the unique 
characteristics are confined to either human or yeast cells, suggesting that the mechanism of 
action/recognition of the ubiquitin system in the two organisms must be different somehow.         
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Introduction  
Polymers of ubiquitin (Ub) are formed on proteasomal substrates in eukaryotic cells by the 
concerted action of three enzymes: The Ub-activating enzyme (E1), a Ub-carrier protein [E2; known 
also as UBC (Ub-conjugating enzyme)] and a Ub ligase (E3) which is the specific substrate-
recognizing element of the system. The  Ub chains typically consist of multiple moieties linked to one 
another via an isopeptide bond between the C-terminal Gly residue of the distal moiety and the ε-NH2 
group of Lys48 of the proximal one (1). 
In addition, the system can also catalyze modification by a single Ub moiety 
(monoubiquitination) or multiple single Ub moieties (multiple monoubiquitinations), each modifying a 
distinct lysine residue (2). Generally, monoubiquitination has been conceived as a non-destructive 
signal. Further, it has been suggested that efficient proteasomal targeting requires a chain with a 
minimal length of four Ub moieties (3). Monoubiquitination is known to be involved in multiple 
biological processes. For example, monoubiquitination of proteins containing a ubiquitin-binding 
domain (UBD) often mediates autoinhibition by a UBD-Ub interaction (4, 5). Signal transduction by 
membrane receptors, such as the EGFR, is attenuated by monoubiquitination-mediated receptor 
internalization (6). The subcellular localization of small GTPases is controlled, among other post-
translational modifications, by monoubiquitination (7, 8), and histone monoubiquitination regulates 
nucleasomal structure, thus affecting gene expression (9). Emerging reports indicate, however, that 
several substrates can be degraded following monoubiquitination (10–13). Partial 
degradation/processing of the p105 precursor of NF-κB, which results in release of the p50 active 
subunit of the transcription factor, is dependent on multiple monoubiquitinations (14). Importantly, 
these findings demonstrate that the proteasome can recognize a single Ub moiety(s), and imply the 
existence of mono- vs polyubiquitination "decision" mechanisms. In this context, a previous study has 
suggested that the chain length required for proteasomal degradation is determined by the size of the 
substrate, and possibly other characteristics that affect the affinity of the modified substrate to the 
proteasome. Specifically, it was suggested that substrates smaller than 150 amino acids are degraded 
following monoubiquitination, whereas longer substrates require longer chains. Thus, a dynamic 
model was proposed, according to which the chain elongates to a point where the affinity to the 
proteasome is high enough to secure a stable binding of the conjugated substrate, its concomitant 
detachment from the E3, and its subsequent degradation (15). Another study demonstrated that 
restricting the number of ubiquitinatable Lys residues can switch the mode of modification necessary 
for degradation from multiple monoubiquitinations to polyubiquitination, suggesting that in the cell, 
the masking of Lys residues by protein-protein interactions or post translational modifications can 
affect the mode of ubiquitination (11).  
However, all these studies have been carried out using specific substrates. Therefore, general 
conclusions regarding monoubiquitination-dependent degradation mechanisms, the population of 
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substrates that are degraded following this modification, and importantly, whether they have common 
distinct characteristics, have remained limited. 
In this study, we employed a systematic proteomic approach for the identification and 
characterization of monoubiquitination-dependent proteasomal substrates. By silencing the 
endogenous WT Ub followed by expression of non-polymerizable lysine-less Ub, we identified 
numerous substrates in both mammalian and yeast cells that are targeted by the proteasome following 
mono- or multiple monoubiquitinations.  Interestingly, we confirmed a previous hypothesis (15) that 
there is a correlation between the length of the substrate and its requirement for either mono- or 
polyubiquitination, though it is stronger in yeast. Also, the monoubiquitinated substrates are enriched 
in specific pathways (e.g. oxidative stress, carbohydrate transport and components of the ubiquitin-
proteasome system itself), and in humans, are structurally less disordered.     
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Results 
Establishing a system for induction of monoubiquitination in cells   
In general, to model monoubiquitination (or multiple monoubiquitinations), we silenced 
endogenous Ub expression and replaced it with a lysine-less Ub (UbK0). This non-polymerizable Ub 
species, in which all seven Lys residues were replaced with Arg, can modify each Lys in the target 
substrate only once, and cannot be further ubiquitinated (16–19).  
To study monoubiquitination in yeast, we used a modification of a previously described Ub 
replacement method (20). Briefly, all the Ub-coding genes were deleted and replaced by galactose-
inducible Ub (ΔUb strain), and either copper-inducible UbWT or UbK0 (ΔUbUbWT or ΔUbUbK0, 
respectively). Thus, Ub expression can be silenced by adding glucose, and Ub re-expression can be 
induced by adding copper to the growth medium (Figure 1A). To validate Ub silencing and re-
expression, ΔUb, ΔUbUbWT and ΔUbUbK0 yeast strains were treated with glucose and copper. As shown 
in Figure 1B, Ub expression was efficiently suppressed, and both UbWT and UbK0 were markedly 
expressed.  
To assess monoubiquitination in human cells, we used a modification of a previously described 
Ub replacement model in human cultured cells (21). Briefly, endogenous Ub is silenced in U2OS cells 
by a Ub-specific tetracycline-induced shRNA (shUb), and either HA-UbWT or HA-UbK0 is expressed 
following infection with an adenoviral vector (Figure 1A). To evaluate Ub silencing efficiency, we 
monitored Ub and Ub conjugates level in U2OSshUb cells following tetracycline treatment. As 
demonstrated in Figure 1Ci, the level of both Ub and Ub-protein conjugates were significantly 
decreased. In the endogenous Ub-silenced cells, both HA-UbWT and HA-UbK0 were efficiently 
expressed and assembled into high molecular mass conjugates following adenoviral expression 
(Figure 1Cii). It should be noted that the pattern of conjugation appears similar for both UbWT and 
UbK0 expression. This is probably due to the numerous substrates with a broad range of molecular 
mass that are conjugated, and from the possibility that many of them are modified by multiple 
monoubiquitinations.     
To demonstrate Ub replacement using an additional method, we quantified Ub using mass 
spectrometry. As shown in Figure S1A, tryptic digestion of UbWT and UbK0 yields both common and 
differential mass spectrometry (MS)-detectable peptides. To assess Ub replacement in yeast, we 
treated ΔUbUbK0 cells with glucose and copper, and quantified Ub-derived peptides by MS. As 
illustrated in Figure S1B, UbK0 was markedly more abundant than endogenous Ub. To evaluate UbK0 
expression in human cells, we overexpressed HA-UbK0 via adenoviral infection using increasing 
MOIs. As displayed in Figure S1C, UbK0 expression level was MOI-dependent, and significantly 
exceeded the level of endogenous Ub. 
Taken together, these data demonstrate the effectiveness of our Ub replacement strategies, and 
suggest that our experimental systems are suitable for studying protein monoubiquitination. 
7 
 
Systematic identification of monoubiquitination-dependent proteasome substrates 
To identify substrates that are degraded following monoubiquitination, we replaced Ub with 
either UbK0 or UbWT (as a control).  We then used anti-K-ε-GG immunoprecipitation (Figure S2) to 
enrich and quantify by MS GlyGly-modified peptides derived from tryptic digestion of ubiquitinated 
proteins (Figure S2). This method enabled us also to identify ubiquitination sites (Ubsites). To verify 
that the ubiquitinated proteins serve indeed as proteolytic substrates, we monitored also the level of 
non-modified peptides derived from them (Figure 2A). To ascertain reproducibility, we performed 
several independent biological replicates for each model organism, using both SILAC labeling and 
label-free quantification (Table S1). As shown in Figure 2B, identification of the proteins was quite 
reproducible.  Similar to previous data (22), identification of Ubsites within proteins was less 
reproducible.  
This established experimental set-up enabled us to discriminate between proteins degraded 
following modification by mono- (or multiple mono-) ubiquitination, and those that are degraded only 
following polyubiquitination. We calculated the MS signal intensity ratios following either UbK0 or 
UbWT expression for both proteins and immunoprecipitated ubiquitinated sites (denoted ‘protein 
K0/WT intensity ratio’ and ‘site K0/WT intensity ratio’, respectively. See Dataset S1 for raw data). As 
illustrated in Figure 2C and based on K0/WT intensity ratios, we classified ubiquitinated proteins to 
putative monoubiquitination- and polyubiquitination-dependent proteasome substrates as following:     
Monoubiquitination-dependent proteasomal substrates are expected to be unaffected by UbPK0P 
expression. Alternatively, as UbPK0 P expression renders proteasomes less occupied by 
polyubiquitination-dependent substrates, increased proteasome availability may result in accelerated 
degradation of monoubiquitination-dependent substrates. Thus, we required these substrates to: 
(i) have a site K0/WT ratio <1; 
(ii) have a detectable MS signal in at least two independent experiments; and 
(iii) have a protein K0/WT ratio <1 (if the protein is detectable)  
The degradation of a polyubiquitination-dependent substrate is expected to be inhibited upon 
Ub PK0P expression. Consequently, we expect their level to increase. Thus, we require these substrates to: 
(i) have a site K0/WT ratio >1; 
(ii) have a detectable MS signal in at least two independent experiments; and  
(iii) have a protein K0/WT ratio >1 (if the protein is detectable)  
 
A small fraction (<3%) of proteins were identified as belonging to the two groups.  These 
proteins were excluded from the survey.   
Applying these criteria in both yeast and human cells, we identified 90 and 255 
monoubiquitination- and 449 and 328 polyubiquitination-dependent putative proteasomal substrates, 
respectively (Dataset S2). Samples of each group are presented in Table 1, describing gene names and 
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ubiquitinated Lys positions. As expected, the polyubiquitination-dependent substrate group included 
several previously suggested proteasomal substrates, e.g. PDC1, OLE1 and ENO1 in yeast, and 
HIF1A, POLD2 and IER3 in human cells (23, 24). 
Candidate substrate validation 
To validate the results of our algorithm and experimental setup, we monitored the cellular 
stability (using cycloheximide chase) of randomly sampled representative candidate substrates 
following Ub replacement. As demonstrated in Figure 3A, replacing UbWT with UbK0 stabilized ARD1 
in yeast and CDC20 in human cells (polyubiquitination-dependent substrates; Table 1). In contrast, the 
predicted monoubiquitination-dependent substrates, GRE1 in yeast and GOT1 in human cells, 
remained unstable. All four substrates were clearly degraded by the 26S proteasome, as they were 
stabilized following treatment with a proteasome inhibitor (Figure 3B). Taken together, these results 
strongly suggest that our experimental setup is suitable for the systematic identification of 
monoubiquitination-dependent proteasomal substrates.    
Physical characteristics of protein substrates play a role in their mode of ubiquitination:  
(i) Structural disorder   
Evidently, a significant number of proteins are degraded following monoubiquitination (and 
probably also multiple monoubiquitinations) in both yeast and human cells. This observation 
challenges the prevailing paradigm of polyubiquitination being the prerequisite for protein 
degradation. Intriguingly, bioinformatics analysis of the data reveals that yeast and human cells 
significantly differ in their preferences for using the two types of signals. In yeast, the ratio of proteins 
degraded by polyubiquitination vs. monoubiquitination is 5.0 (449/90), whereas in human cells it is 
only 1.3 (328/255). Since the identification method was unbiased, the significant difference in the 
ratios likely points to important differences in the mode of recognition of the ubiquitin-proteasome 
system (UPS) in the two species. Yeast apparently operates much more by the traditional signal, 
polyubiquitin, whereas in humans monoubiquitination is used almost as frequently as 
polyubiquitination to mark proteins for degradation. The difference may arise from a combination of 
factors such as using different sets of conjugating enzymes (E2s and E3s), different preferences for 
local sequence and structural features of substrates, and the recognition elements of the proteasome. 
Some of these issues are addressed below. 
In previous studies, it has been shown that protein ubiquitination and degradation are intimately 
linked with structural disorder. Intrinsically disordered protein regions lack a well-defined tertiary 
structure, yet they fulfil important functional roles linked with their highly flexible and adaptable 
structure (25–27). Structural disorder correlates with all three elements of degradation signals: location 
of the ubiquitin ligase recognition motif on substrates, the Lys residue(s) to which ubiquitin is 
attached, and a nearby long disordered region (LDR, a region of at least 30 consecutive disordered 
residues) that initiates the unfolding of the substrate engaged with the proteasome (15, 28–30). 
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Structural disorder may also be required for ubiquitin conjugation itself, in two different ways. It is 
repeatedly reported that the mutation of the Lys residue that is the site of modification does not usually 
abrogate sensitivity to UPS degradation (11, 31), because flexibility of the substrate enables multiple 
modifications on neighboring Lys resides. By a similar logic, the buildup of a polyubiquitin chain can 
also benefit from local structural disorder, because it enables the processive addition of subsequent 
ubiquitin moieties to the end of the growing polyubiquitin chain.  
To test if these disorder features may be related to the use of mono- vs. polyubiquitination, we 
tested if predicted structural disorder of proteins differs in the different datasets (Figure 4A). We found 
significant differences between yeast and human proteins: in yeast, the occurrence of structural 
disorder does not differ between mono- and polyubiquitinated substrates, whereas in human cells, 
structural disorder prevails in polyubiquitinated substrates. Given that polyubiquitin is a stronger 
signal, we presume that structural disorder is primarily used for the buildup of the polyubiquitin chain. 
Since yeast relies more heavily on polyubiquitination, yet its polyubiquitinated substrates do not have 
more disorder, it is possible that their E3 ligases differ from humans in some critical features.  These 
can be their number/redundancy, structural disorder, or binding heterogeneity, the structural disorder 
of which ensures processive addition of ubiquitin moieties in the ubiquitin chain.  
These differences also have to manifest themselves in the local disorder of the protein chain 
around the ubiquitinated Lys residues. In general, the sites of post-translational modifications (PTMs) 
in proteins tend to exhibit local disorder, as studied in detail for phosphorylation (32) and also 
ubiquitination (28). In our entire dataset, the lysines that are the sites of ubiquitination tend to be 
locally disordered, but even more importantly, they show a highly characteristic difference between 
the two species. In yeast, monoubiquitination sites, whereas in human cells polyubiquitination sites, 
are significantly more disordered (Figure 4B). Our interpretation, again, is that these differences point 
to likely differences in the UPS in the two species. In yeast, polyubiquitination is robust, and it is the 
rare monoubiquitination sites that have to be supported by local disorder, probably more for initiation 
of degradation than modification (29). In human cells, the sites of polyubiquitination are significantly 
more disordered, probably as much for the processive build-up of the polyubiquitin chain as for 
initiation of degradation (as suggested above). These are genuine differences and do not result from 
the natural tendency of lysines to be locally disordered, which, as disorder-promoting amino acids, 
tend to be located in disordered regions of proteins (33) (Figure S3A). 
The distinction between the signaling strength and functionality of mono- and polyubiquitin 
chains in yeast and human cells is also reflected in characteristic differences in the proximity of LDRs 
to Ubsites, which might be the sites of initiation of proteasomal degradation (28–30). The need of such 
assistance for monoubiquitination sites in yeast is apparent from the larger proportion of such sites that 
are close to an LDR (Figure 4C), and probably also by a larger proportion of such sites that are close 
to the termini of the proteins, which are generally flexible (Figure S3B).  
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Conservation in evolution can be an important indicator of the functionality of PTM sites. For   
example, functional phosphorylation sites (i.e. were shown to have a functional role by direct or 
indirect evidence - e.g. mutagenesis and/or functional assays) evolve significantly slower than those 
without evidence for a functional role (34). Interestingly, Ubsites are significantly more conserved in 
human cells than in yeast (Figure S3C) (these differences are significant because the phylogenetic 
coverage of the respective multiple alignments is comparable). These results infer that yeast sites are 
under a significantly lower evolutionary pressure, which may point to the fact that they are 
functionally more promiscuous. 
Physical characteristics of the proteins play a role in their mode of ubiquitination:  
(ii) size of the protein  
In a previous study, we have shown that substrates degraded by the attachment of a single 
ubiquitin chain are usually shorter than 150 amino acids (15), which suggests that monoubiquitination 
is a weaker signal. In accord, there is significant enrichment of shorter proteins among yeast 
monoubiquitinated substrates, and also a similar trend in humans (Figure S3D). This is particularly 
true, if we take only average-length proteins (below 600 amino acids) into consideration. This 
difference is not reflected in a preference of multiple modifications in longer proteins: there are no 
significant differences in the length of substrates that are degraded after the attachment of a single vs. 
multiple mono- or polyubiquitin chains (Figure S3E).  
Monoubiquitination- and polyubiquitination-dependent substrates are differentially enriched in 
specific biological processes 
To characterize the two different modes of ubiquitination in a cellular function perspective, we 
searched for enriched Gene Ontology (GO) terms, using the GOrilla tool (35, 36). As illustrated in 
Figure 5A, it appears that monoubiquitination-dependent proteasomal substrates are enriched in 
oxidative stress response and carbohydrate transport pathways. As presented in Figure 5B, molecular 
function-specific GO terms were also identified.  For example, monoubiquitination-dependent 
substrates were found enriched among ribosomal and proteasomal subunits. Similarities between the 
mono- and polyubiquitinated substrates were also observed, as Ub system components were enriched 
in both groups. Interestingly however, monoubiquitinated substrates consisted of mostly Ub ligases, 
E3s (e.g. HERC3, ITCH, XIAP), whereas polyubiquitinated substrates were enriched with Ub-
conjugating enzymes, E2s (e.g. UBE2J1, UBE2T, UBE2L6). 
 
 
  
11 
 
Ubiquitination site sequence analysis reveals unique patterns  
Previous studies have demonstrated motifs and sequence patterns specific for protein post-
translational modifications such as phosphorylation, acetylation and SUMOylation (29, 30, 37, 38). To 
identify Ubsite motifs, we analyzed our data using the Motif-X algorithm (39). Consistent with 
previous findings (24), no specific motif was found when analyzing all identified Ubsites in either 
yeast or human cells. To analyze Ubsite amino acid composition, all identified Ubsites were 
examined. We constructed an alignment of peptides that are surrounding each modified Lys residue. 
Residue- and position-specific amino acid occurrences were calculated and were compared to the 
corresponding proteomic occurrence in a lysine-centered peptide. As depicted in Figure S4A, 
ubiquitination sites demonstrated residues-specific enrichment (e.g. Ala, Gly, Gln) and under-
representation (e.g. Cys, His, Lys, Met, Trp) for both yeast and human cells. Enrichment of Glu, and 
to a lesser extent Asp, was specific to yeast sites. Importantly, for several amino acids, the enrichment 
factor depended on the proximity to the modified Lys, suggesting that these residues can affect 
conjugation mechanisms. 
 To compare the ubiquitination site composition of monoubiquitination- vs. polyubiquitination-
dependent substrates, we performed the above analysis for each group separately. As shown in Figures 
S4B and S4C, each group displays a unique pattern of enrichment factors, and several differences can 
be observed between the patterns of monoubiquitination- and polyubiquitination-dependent substrates.  
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Discussion 
In this study we identified 90 yeast and 255 mammalian proteins that are degraded by the 
proteasome following monoubiquitination. These significant numbers point to a much broader 
phenomenon to what was considered until recently as an exception. Therefore, it allows for analysis 
that sheds light on the mechanisms that underlie the different modes of ubiquitination. Being aware of 
the limitations of a proteomic screen, we assume the numbers are larger.         
Experimentally, we replaced UbWT with UbK0 in cells to enforce monoubiquitination.  This 
strategy has been used successfully to inhibit polyubiquitination-dependent proteasomal degradation 
(14, 17–19). Other methods to study monoubiquitination have been reported, such as inhibition of 
polyubiquitin chain formation by methylated Ub (40), or detection by Western Blotting of specific 
substrates that appear to be monoubiquitinated (10). However, using methylated Ub is limited to cell 
free systems, and using endogenous Ub can identify only individual substrates. Therefore, these 
methods limit the ability to identify and characterize the broad population of target substrates degraded 
by the proteasome following mono- and polyubiquitination. Thus, UbWT-to-UbK0 replacement in cells 
seemed to be the most suitable strategy for our objective of carrying out a proteome-wide screen to 
identify these two distinct populations.     
Importantly, although efficient UbK0 expression inhibits polyubiquitination, it may still support 
the conjugation of several UbK0 molecules to a protein substrate, resulting in multiple-
monoubiquitinations. In our study, we included mono- and multiple-monoubiquitinated substrates in 
the same group, as discriminating between the two is complicated experimentally.  
Importantly, in our survey we decided not to use proteasome inhibitors as a tool to identify 
substrates that are nevertheless degraded following Ub replacement. The reason being that in human 
cells infected with adenoviral HA-UbWT, we could not observe up-regulation of Ub conjugates 
following treatment with a proteasome inhibitor (Figure S5A).  It should be noted that the proteasome 
in the cells was active (Figure S5B), and its inhibition was efficient (Figure S5C). This finding is 
consistent with partial proteasome inhibition by free Ub chains that are accumulated due to the high 
level of HA-UbWT (41). Also, the use of proteasome inhibitors is challenging in yeast cells, as low 
permeability results in low cellular concentration of the drugs (42). Therefore, we have adapted 
alternative classification criteria to identify mono- vs. polyubiquitinated proteasomal substrates based 
on MS analyses of the proteome and ubiquitome under normal conditions and under conditions where 
monoUb is predominant (see under Results and in Figure 2B).  To confirm our results and to 
nevertheless relate them to proteasomal degradation, we integrated data from previous studies (23, 24, 
43) and constructed a reference list of known ubiquitin-proteasome substrates (Dataset S3). Compared 
to this list, our polyubiquitination-dependent substrates were highly enriched with known proteasomal 
substrates in both yeast and human cells (P-value = 6.90x10-23 and P-value = 5.06x10-5, respectively, 
by hypergeometric test). This strongly suggests that our experimental model is faithful and offers a 
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reliable method for the identification of UPS substrates. Furthermore, we validated biochemically that 
several mono- and polyubiquitination-dependent candidates emerged from the screen do indeed 
belong to their respective expected categories (Figure 3). 
It is interesting to refer to specific proteins that were identified in previous studies as targeted by 
monoubiquitination.  Thus, Syndecan-4 (12) did exhibit site K0/WT ratio <1 (for Lys105), but was 
detected in one replicate only. Cks-2 (15) displayed protein K0/WT ratio <1 at the protein level, but 
had conflicting ratios at site level. Other substrates including Pax-3 (13) and α-synuclein (10) could 
not be detected, probably due to low abundance in the bone-derived U2OS cells (44). Taken together, 
it seems that our results are in agreement with random previous data, but should be further 
substantiated by experiments in cells from different tissues.  
Notably, since we did not use proteasome inhibitors, some of our monoubiquitination-dependent 
candidates may actually be degraded via other cellular pathways. Accordingly, it was previously 
shown that receptor tyrosine kinases (RTKs) (45) and other membrane proteins are subjected to 
monoubiquitination-dependent lysosomal degradation.  
From the bioinformatics analyses of the substrates, several important and intriguing conclusions 
can be drawn. First, in agreement with previous studies in which it was shown that substrates of up to 
150 residues can be degraded following monoubiquitination (15), we found that the distribution of 
monoubiquitination-dependent substrates is shifted towards shorter proteins (Figure S3D).  
Further, a difference between yeast and human is also apparent when comparing the ratio of 
monoubiquitination- and polyubiquitination-dependent substrates. Yeast relies more heavily on 
polyubiquitination, whereas human cells use both monoubiquitination and polyubiquitination with a 
similar frequency. This difference can be interpreted if structural disorder is considered as shown by 
our own data (Figures 4 and S3), and if we assume that a single ubiquitin moiety is a weaker signal for 
degradation than polyubiquitin. As suggested, local structural disorder is involved in various steps of 
the UPS cascade, from recognition motifs of E3 ligases through local disorder of ubiquitination sites to 
an LDR initiation site of substrate unfolding (28–30).  
We have screened our monoubiquitination-dependent substrates for enriched biological process-
related GO terms, and found a highly significant over-representation of genes associated with 
carbohydrate transport and oxidative stress response pathways (Figure 5A). Since carbohydrate 
transporters are plasma-membrane proteins, this finding is consistent with previous studies which 
demonstrated membrane receptors down-regulation via monoubiquitination-mediated endocytosis 
(46). Notably, as this pathway results in lysosomal/vacuolar rather than proteasomal degradation, this 
finding highlights the challenge in distinguishing between these two degradation modes using our 
experimental system. Oxidative stress was shown to activate cellular signal transduction cascades, and 
to result in gene expression modulation (47). The enrichment of oxidative stress response proteins in 
our monoubiquitination-dependent substrates may suggest that they are regulated by a common 
monoubiquitinating E3 ligase(s). Thus, oxidative stress-mediated down regulation of this putative E3 
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may result in up regulation of oxidative stress pathway components and activate the respective cellular 
response. Consistently, microarray experiments have shown that the expression of the E3s UBR1 and 
HUL4, and the E2s CDC43, RAD6 and UBC11, is decreased following exposure to oxidative stress 
(48).  
UPS components were enriched in both groups (Figure 5B). This finding most likely represents 
the previously reported autoubiquitination of E2s (49–51) and E3s (52–54). Our findings show that 
E3s are preferably classified as monoubiquitination-dependent substrates. 
In this study, we have determined the sequence positions of thousands of ubiquitinated lysines. 
The unsuccessful attempts to identify a ubiquitination-site motif in this study and in others (24, 55) 
reflect site-level promiscuity which is supported by low ubiquitination sites conservation across 
eukaryotic species (55), and by the flexible selection of the ubiquitinated lysines within a given 
substrate (11, 31). Additionally, we used position-specific analysis of relative amino acid abundance to 
characterize ubiquitination sites (Figure S4). This method yields a more thorough representation of the 
amino acid composition, and reflects both enrichment and under-representation trends. According to 
the notion of promiscuity, a ubiquitination site should merely provide a sterically available ε-amino 
group of a Lys residue. Consistently, we found enrichment of small residues (e.g. Ala and Gly) and 
decrease in bulky (e.g. Trp) residues in the proximity of the ubiquitinated Lys. The depletion of Pro at 
position -1 also supports this concept, since Pro disrupts the protein's secondary structure and might 
impair the solvent accessibility of a following Lys residue.   
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Experimental Procedures 
Adenovirus-mediated Ub replacement in human cells 
For Ub silencing, U2OSshUb [described in (56)] cells were treated with 1 µg/ml tetracycline for 24 hr. 
Fresh tetracycline and adenoviruses encoding either HA-UbWT or HA-UbK0 were  added, and cells 
were incubated for additional 24 hr. 
Ub replacement in yeast 
The construction of ΔUb strain was described previously [SUB328; (57)]. Briefly, endogenous Ub 
genes were deleted and replaced with a Ub gene expressed under a Gal promoter.  To construct 
ΔUbUbWT and ΔUbUbK0 strains, ΔUb yeast cells were transformed with pUb39 UbWT and pUb39 UbK0, 
respectively (both genes are under the Cup1 promoter). To replace the Gal-induced Ub, ΔUbUbWT and 
ΔUbUbK0 yeast cells were grown to 1.0 OD600nm in standard Hartwell's complete medium (HC) without 
glucose, supplemented with 2% galactose and 2% raffinose. Cells were then washed in DDW to 
remove galactose and raffinose, and re-suspended in HC medium with glucose and 50 µm CuSO4.  
Cells were incubated for 16 hr at 30oC, collected by centrifugation, washed in DDW and frozen in 
liquid N2.  
Ubiquitination sites detection using GG-modified peptide enrichment 
Dried peptides (see under Sample preparation for mass spectrometry in Supplemental Information) 
were re-suspended in immunoaffinity purification (IAP) buffer (50 mM MOPS/NaOH pH 7.2, 10 mM 
Na2HPO4 and 50 mM NaCl), and cleared by centrifugation. Supernatants were adjusted to pH 7.0 
with NaOH and incubated with immobilized anti-K-ε-GG antibody (Cell Signaling Technology) at 
4oC for 3 hr. Beads were washed with IAP buffer and then with a wash buffer (500 mM NaCl, 3 mM 
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 0.1% octylglucoside, pH 7.4). GG-modified peptides were 
eluted with 0.2% trifluoroacetic acid (TFA), desalted on C18 tips, and eluted in two fractions of 20% 
and 80% acetonitrile. Peptides were analyzed as described under Mass spectrometry in Supplemental 
Information. 
 
For additional experimental procedures, see Supplemental Information. 
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Figure Legends 
Figure 1. Replacement of endogenous Ub by UbK0 in yeast and mammalian cells 
(A) Workflow describing Ub silencing and re-expression (see a detailed description under 
Experimental Procedures). (B) Ub replacement in yeast cells. ΔUb, ΔUbUbWT and ΔUbUbK0 yeast cells 
were treated for Ub silencing and Ub re-expression as indicated. Yeast cells were analyzed by 
trichloroacetic acid (TCA) lysis followed by SDS-PAGE and WB using the indicated antibodies. (C) 
Ub replacement in human cells. <i> Ub silencing. To silence Ub, U2OSshUb cells were treated with 
tetracycline (1 μg/ml) for the indicated times. <ii> Ub re-expression. Following Ub silencing, cells 
were infected with viral vectors expressing UbWT or UbK0. In both panels, lysates were analyzed via 
SDS-PAGE followed by WB using the indicated antibodies.  
Figure 2. Identification of monoubiquitination- and polyubiquitination-dependent proteasome 
substrates  
(A) Experimental workflow. See a detailed description under Results. (B) Ubiquitination sites and 
ubiquitinated proteins identified in independent experiments. See Table S1 for experiment names. (C) 
The algorithm used for classification to monoubiquitination- and polyubiquitination-dependent 
substrates.  
Figure 3. Validation of representative candidate substrates degraded by the proteasome 
following mono- and polyubiquitination 
(A) Upper panels: MCF7 cells were co-transfected with plasmids coding for GOT1-HA or CDC20-
HA along with plasmids coding for UbWT or UbK0 as indicated. Lower panels: ΔUbUbWT and ΔUbUbK0 
yeast cells were transformed with plasmids coding for GRE1-HA or ARD1-HA, and Ub replacement 
was carried out as described under Figure 1. In all experiments, substrate stability was monitored as 
described under Experimental Procedures. (B) Upper panels: MCF7 cells were transfected with either 
GOT1-HA or CDC20-HA, followed by the treatment with epoxomicin (2 µM, 24 hr) as indicated. 
Lower panels: ΔPDR5 yeast cells (strain Y12409 from the EUROSCARF collection) were 
transformed with plasmids coding for either ARD1-HA or GRE1-HA. Strains were treated with 
cycloheximide (CHX) and bortezomib (100 µM each) as indicated. Samples were collected at the 
indicated time points. Cell lysates were analyzed via SDS-PAGE followed by WB using the indicated 
antibodies. 
Figure 4. Yeast and human substrates demonstrate distinct patterns of structural disorder 
(A) Human polyubiquitinated substrates are more disordered than monoubiquitinated substrates. The 
distribution of overall disorder content in mono- and polyubiquitinated substrates is plotted for yeast 
and human. Overall disorder content is the fraction of predicted disordered residues in a given protein 
sequence. The distribution for the reference proteome corresponding to each species is shown for 
comparison. Dotted vertical lines correspond to the average values for the distribution. (B) Local 
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disorder at the ubiquitination sites is more prominent in yeast monoubiquitination substrates and in 
human polyubiquitination substrates. The distribution of local disorder score is plotted for mono- and 
polyubiquitinated sites from yeast and human. The disorder profile for each sequence is first 
calculated using IUPred and then the average disorder score of a 21-residue sequence window 
centered on each Ubsite is calculated. The distribution for the reference proteome corresponding to 
each species is shown for comparison. Dotted vertical lines correspond to the average values for the 
distribution. (C) The distance of Ubsites from their nearest LDR (see Experimental Procedures for 
definition) is plotted for yeast and human sites. The averages of the distributions are not shown here 
for the sake of clarity.  
Figure 5. Analysis of molecular functions and involvement in different cellular processes for 
mono- and polyubiquitination-dependent substrates. 
Monoubiquitination- and polyubiquitination-dependent substrate groups were analyzed for Gene 
Ontology (GO) term enrichment using the GOrilla tool, as described under Experimental Procedures. 
(A) Biological Process GO term analysis for yeast substrates. (B) Molecular Function GO term 
analysis for human substrates. 
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Supplemental Figures and Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Mass spectrometric verification of replacement of endogenous Ub by UbK0 in yeast 
and mammalian cells.  
(A) Ubwt- and UbK0-derived tryptic peptides used for mass spectrometric quantification of UbK0 
expression. Human Ub sequence is shown. The indicated differential and common peptides 
correspond also to the yeast Ub. (B) ΔUb, ΔUbUbWT and ΔUbUbK0 yeast cells were treated for Ub 
replacement as indicated. In all experiments, total Ub abundance (K0 and WT species) was assessed 
based on the relative MS intensity of the common peptide and UbWT and UbK0 abundances were 
assessed based on the relevant differential peptide. Ub replacement and MS analysis were performed 
as described under Experimental Procedures. MS peaks representing the indicated peptides are shown 
with values representing column retention times (upper value; in minutes) and m/z ratio (lower value). 
(C) U2OSshUb cells were either left untreated or treated for Ub replacement with UbK0 using the 
indicated MOI. Data were processed as described under (B).    
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Figure S2. Ubiquitination sites enrichment.  
Schematic illustration of isolation of GG-modified peptides using anti-K-ε-GG immunoprecipitation. 
For detailed description, see under Experimental Procedures. 
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Figure S3. Analyses of different characteristics of ubiquitinated substrates.  
(A) Boxplots showing the local disorder scores for Ubsites, NonUbsites and all lysines in the reference 
proteome. Ubsites correspond to the identified ubiquitination sites in each protein and NonUbsites are 
the remaining lysines from the proteolytic substrates. The Y-axis corresponds to the average IUPred 
score of 21-residue sequence windows flanking each lysine. (B) Plot showing the distance of yeast 
(left) and human (right) Ubsites from their nearer protein chain terminus. Dotted lines represent the 
average values of each distribution. (C) Plot showing Ubsite residue conservation across orthologous 
proteins (see Experimental Procedures for details). On the X-axis, 0.0 corresponds to a completely 
variable Ubsite, whereas 1.0 indicates a fully conserved Ubsite. Dotted lines represent the average 
values of each distribution. (D) Length of substrates that undergo monoubiquitination- and 
polyubiquitination dependent degradation. The plot is showing the length distribution of mono- and 
polyubiquitinated substrates from yeast (left) and human (right). The reference proteome 
corresponding to each species is shown for comparison. Dotted vertical lines correspond to the 
average values for the distribution. (E) Boxplots of the distribution of sequence lengths for proteins 
containing a single or multiple Ubsites. The plots show data from yeast and human cells and from 
mono- and polyubiquitinated proteins. Outliers are not shown. 
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Figure S4. Analysis of amino acids occurrences around ubiquitination sites.  
Analysis of sequence windows with ubiquitinated lysines in their center. Residue- and position-
specific enrichment factors (EF) were calculated as described under Experimental Procedures. (A) All 
identified ubiquitination sites in yeast (left panel) and in human (right panel). (B) Yeast ubiquitination 
sites of polyubiquitination- (left panel), and monoubiquitination- (right panel) dependent substrates. 
The highlighted coordinates represent major pattern differences between mono- and polyubiquitinated 
substrates in which: �𝐸𝐸𝑝𝑝𝑝𝑝 − 𝐸𝐸𝑚𝑝𝑚𝑝� > 4. (C) Same as in (B) but for human substrates. 
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Figure S5. Measurement of ubiquitin-proteasome system activity following Ub replacement in 
U2OSshUb cells.  
(A) Where indicated, endogenous Ub was replaced by HA-UbWT in U2OSshUb cells as described under 
Experimental Procedures. Cells were further treated as indicated with MG132 at 20 µM for 4 hr. 
Lysates were analyzed by SDS-PAGE followed by WB using the indicated antibodies. (B) 
Endogenous Ub was replaced by HA-UbWT in U2OSshUb cells. The stability of Ub-conjugates was 
monitored following addition of cycloheximide for 6 hr as described under Experimental Procedures. 
(C) U2OSshUb cells were treated for Ub replacement by HA-UbWT and for proteasome inhibition with 
MG132 as indicated. Proteasome activity was measured by a fluorescence-based assay as described 
under Experimental Procedures. 
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Table S1.  Quantitative experiments for the identification of monoubiquitination-dependent 
proteasomal substrates 
# Experiment Model organism Experimental setup Number of identified peptides 
Y1 yeast label free 5164 
Y2 yeast label free 3257 
Y3 yeast label free 3530 
H1 human label free 5509 
H2 human label free 2440 
H3 human SILAC 1156 
H4 human label free 2561 
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Supplemental Experimental Procedures 
Materials 
Anti-Ub was described previously (1), anti-HA (16B12) was from Covance, and anti-actin and anti-
tubulin were from Millipore. Anti K-ε-GG Immunoaffinity Beads were from Cell Signaling 
Technology. Suc-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC) was from Boston Biochem. Materials 
for SDS-PAGE and Bradford reagent were from Bio-Rad. Tissue culture sera, media, and supplements 
were from Biological Industries (Bet HaEmek, Israel). Peroxidase-conjugated secondary antibodies 
were from Jackson ImmunoResearch Laboratories. N-carbobenzoxy-L-leucyl-L-leucyl-leucinal 
(MG132) and epoxomicin were from Calbiochem. Reagents for enhanced chemiluminescence (ECL) 
were from Pierce. JetPEIPTM P cell transfection reagent was from Polyplus. Restriction and modifying 
enzymes were from New England Biolabs. Oligonucleotides were synthesized by Sigma. All other 
reagents were of high analytical grade.  
Plasmids 
All of the plasmids were constructed and manipulated using standard molecular biological techniques. 
For liposome-mediated transient cell transfection, Flag-Ub PWTP and Flag-Ub PK6,11,27,29,33,48,63R P (Flag-Ub PK0 P) 
were subcloned into pCAGGS (2), and GOT1-HA and CDC20-HA were subcloned into pCS2. For 
adenovirus preparation, HA-Ub PWTP and HA-Ub PK0 P were subcloned into pAd/CMV/V5-DEST. For yeast 
transformation, UbPWTP and Ub PK0P were subcloned into pUb39 (3), and ARD1-HA and GRE1-HA were 
subcloned into pCM190. 
Cultured cells 
U2OSPshUbP cells (4) were grown at 37PoPC in DMEM supplemented with 10% fetal calf serum and 
antibiotics (penicillin–streptomycin). MCF7 cells were grown 37PoPC in the same medium supplemented 
with insulin (100 units/ml). 
Protein concentration measurement 
Protein concentration was measured by the Bradford method  (5) using BSA as the standard. 
Protein detection 
For Western blotting (WB), proteins were resolved via SDS-PAGE, transferred to nitrocellulose (or 
PVDF) membrane, and incubated with the appropriate antibodies.  
Yeast transformation 
The different strains of Saccharomyces cerevisiae were transformed with plasmids coding for the 
proteins of interest using the PEG/LiAc [poly(ethylene glycol)/lithium acetate] method (6), followed 
by appropriate selection. 
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Mammalian cell transfection 
Transient transfections of mammalian cells with plasmids containing cDNAs coding for proteins of 
interest were carried out using the jetPEITM transfection reagent according to manufacturer’s 
instructions. 
Monitoring protein stability 
Protein synthesis was inhibited by adding 100 µg/ml cycloheximide. Samples were collected at the 
indicated times, and proteins of interest analyzed by SDS-PAGE followed by WB using the indicated 
antibodies. 
Preparation of adenoviral vectors 
HEK293 cells were transfected with pAd/CMV/V5-DEST (AdEasyTM Vector System) encoding the 
genes of interest. Small and large scale virus amplifications were performed according to the 
manufacturer's instructions, followed by purification of the viral particles on iodixanol gradient as 
described previously (7). Viral titer was determined by MOI test according to the manufacturer's 
instructions. 
Fluorescence-based proteasome activity assay 
Cells were lysed in 0.3% CHAPS buffer (20 mM HEPES, 100 mM NaCl, 1 mM EDTA, 1.5 mM 
MgCl2, 0.3% CHAPS, 1 mM DTT, 2.5 mM ATP, and protease inhibitor cocktail), and proteasomes 
were immobilized onto agarose to which anti-α6 was bound. Beads to which the proteasomes were not 
immobilized were used as control. Beads were washed twice with 0.03% CHAPS buffer. Where 
indicated, MG132 (100 µM) was added to the immobilized proteasomes and the mixture was 
incubated at 37oC for 10 min. Next, proteasomes were incubated at 37oC for 30 min with the indicated 
concentrations of Suc-LLVY-AMC in a reaction buffer (40 mM Tris-HCl pH 7.2, 2 mM DTT, 5 mM 
MgCl2, 10 mM creatine phosphate, 0.1 mg/ml creatine phosphate kinase, 5 mM ATP). Reaction was 
stopped by adding 1% SDS, and fluorescence was measured at Ex. 360nm/Em. 460nm. 
Cell lysis 
Yeast cell lysates for WB were prepared by Trichloroacetic acid (TCA) precipitation as described (8). 
Yeast lysates for MS analysis and anti-K-ε-GG IP were prepared by suspending cell pellets in urea 
buffer (8 M urea, 100 mM Tris-HCl pH 8.0, 10 mM iodoacetamide), followed by shaking with 0.5 mm 
glass beads for 25 min at room temperature. The resulting lysates were cleared by centrifugation. 
Human cells were lysed by adding urea buffer, followed by brief sonication and clearing by 
centrifugation. 
Sample preparation for mass spectrometry 
Cells were harvested and lysed as described under Cell lysis. 2-3 mg of protein in 8 M Urea and 100 
mM ammonium bicarbonate, were incubated with DTT (2.8 mM; 30 min at 60oC), modified with 
iodoacetamide (8.8 mM; 30 min at room temperature in the dark), and digested (overnight at 370C) 
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with modified trypsin (Promega; 1:50 enzyme-to-substrate ratio) in 2 M Urea and 25 mM ammonium 
bicarbonate. Additional second trypsinization was carried out for 4 hours. The tryptic peptides were 
desalted using Sep-Pak C18 (Waters) and dried. 10 µg of the total protein were used for proteome 
analysis as described under Mass spectrometry, and the remaining material was used for ubiquitination 
sites analysis as described under Ubiquitination sites detection using GG-modified peptide enrichment.
  
Mass spectrometry 
Tryptic peptides were analyzed by LC-MS/MS using a Q Exactive plus mass spectrometer (Thermo 
Fisher Scientific) fitted with a capillary HPLC (easy nLC 1000, Thermo). The peptides were loaded 
onto a C18 trap column (0.3 x 5 mm, LC-Packings) connected on-line to a home-made capillary 
column (20 cm, internal diameter 75 micron) packed with Reprosil C18-Aqua (Dr. Maisch GmbH, 
Germany) in solvent A (0.1% formic acid in water). The peptides mixture was  resolved with a 5-28% 
linear gradient of solvent B (95% acetonitrile with 0.1% formic acid) for 180 min followed by a 5 min 
gradient of 28-95% and 25 min at 95% acetonitrile with 0.1% formic acid in water at a flow rate of 
0.15 μl/min. Mass spectrometry was performed in a positive mode (m/z 350–1800, resolution 70,000) 
using repetitively full MS scan followed by collision-induced dissociation (HCD at 35 normalized 
collision energy) of the 10 most dominant ions (>1 charges) selected from the first MS scan. A 
dynamic exclusion list was enabled with exclusion duration of 20 sec. 
Data analysis 
The mass spectrometry raw data were analyzed by the MaxQuant software (version 
1.4.1.2, http://www.maxquant.org) for peak picking and quantification. This was followed by 
identification of the proteins using the Andromeda engine, searching against the human or the yeast 
UniProt database with mass tolerance of 20 ppm for the precursor masses and for the fragment ions. 
Met oxidation, N-terminal acetylation, N-ethylmaleimide and carbamidomethyl on Cys, GlyGly on 
Lys, and phosphorylation on Ser, Thr and Tyr residues, were set as variable post-translational 
modifications. Minimal peptide length was set to six amino acids and a maximum of two mis-
cleavages was allowed. Peptide- and protein-level false discovery rates (FDRs) were filtered to 1% 
using the target-decoy strategy. Protein tables were filtered to eliminate the identifications from the 
reverse database and from common contaminants. The MaxQuant software was used for label-free 
semi-quantitative analysis [based on extracted ion currents (XICs) of peptides], enabling quantification 
from each LC/MS run for each peptide identified in any of the experiments. In samples that were 
SILAC-labeled, quantification was also done using the MaxQuant 1.4.1.2 software. Data merging and 
statistical tests were done by the Perseus 1.4 software. 
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Gene Ontology term enrichment analysis (GOrilla) 
GO term analysis was performed by the Gorilla web tool (9, 10), using the two unranked lists running 
mode. We used the monoubiquitination- or polyubiquitination-dependent proteasome substrate groups 
as target lists, and the complete proteome as a background list. Both yeast and human data were 
analyzed. 
Statistical analysis 
To compare protein sequence lengths of monoubiquitination- and polyubiquitination-dependent 
proteasomal substrates, length distribution histograms were generated. Statistical significance of 
differences was determined by the Mann-Whitney U-test. To analyze ubiquitination sites amino acid 
composition, peptides containing GG-modified lysines in their center were aligned, and residue- and 
position-specific amino acid occurrences (OC) were calculated. As a control, the corresponding 
proteome’s amino acid occurrences in lysine-centered peptides were estimated (OCcontrol), using 
lysines from 1,000 random proteins. The statistical significance of enrichment or depletion for each 
amino acid in every position was determined by the binomial test, and the enrichment factor (EF) was 
calculated as following: 
 
𝐸𝐸 = �− log(𝑃𝑣𝑣𝑝𝑣𝑣) ;   𝑂𝑂𝑂𝑂𝑐𝑐𝑐𝑐𝑐𝑐𝑐 > 1    log(𝑃𝑣𝑣𝑝𝑣𝑣) ;   𝑂𝑂𝑂𝑂𝑐𝑐𝑐𝑐𝑐𝑐𝑐 < 1 
Thus, increasing positive EF values represent a more significant enrichment, and increasing negative 
EF values represent a more significant depletion. 
 
Prediction of structural disorder 
IUPred (11) software was used to predict structural disorder using amino acid sequences as input. 
IUPred output scores were determined for each residue (ranging between 0 – 1); scores greater than 
0.5 indicate disordered residues (the ‘long’ default mode of IUPred was used). Using the IUPred 
scores, long disordered regions (LDRs) were defined as consecutive stretches of at least 30 disordered 
residues (breaks of up to 3 consecutive ordered residues within an LDR were permitted). Statistical 
tests for calculating P values were carried out using the Mann-Whitney U test. 
Ortholog alignments and calculation of ubiquitination site conservation 
Pre-computed multiple sequence alignments of orthologs were obtained from Discovery@Bioware 
(http://bioware.ucd.ie/~compass/biowareweb/) and used to calculate the fraction of aligned sequences 
in which lysines were retained in orthologous sequences for identified Ubsites. Statistical tests for 
calculating P values were carried out using the Mann-Whitney U test. 
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